Stock Events

Stock Events

Roivant Sciences 

$34.93
82
+$0.52+1.51% Friday 20:00
+$0.35+1%Friday 23:58After hours

Statistics

Day High
34.97
Day Low
34.92
52W High
37.97
52W Low
12.54
Volume
221,172
Avg. Volume
-
Mkt Cap
25.23B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.36
-0.15
0.07
0.28
Expected EPS
-0.360849
Actual EPS
N/A

Financials

-3,629.19%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
8.26MRevenue
-299.77MNet Income

Analyst Ratings

41.00Average Price Target
The highest estimate is 42.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ROIV. It's not an investment recommendation.
Microsoft
20
MSFT
NVIDIA
19
NVDA
Amazon
18
AMZN
Apple
16
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines that address serious diseases in areas similar to Roivant's focus, making them direct competitors in the biopharma sector.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a broad range of products in various therapeutic areas, competing with Roivant Sciences in the development and marketing of pharmaceuticals and therapies.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that operates in the same therapeutic areas as Roivant, including the development of prescription medicines, vaccines, biologic therapies, and animal health products.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, Inc. is a biopharmaceutical company that researches, develops, and commercializes drugs in areas overlapping with Roivant's interests, particularly in virology, making them a key competitor.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie is a research-based biopharmaceutical company that develops and markets advanced therapies. It competes with Roivant in several therapeutic areas, including immunology and oncology.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is one of the world's leading biotechnology companies, focusing on areas such as cardiovascular disease and oncology, which are also of interest to Roivant, positioning them as competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of medicines for serious medical conditions, directly competing with Roivant in the biopharmaceutical field.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals Incorporated is known for creating transformative medicines for people with serious diseases, including cystic fibrosis, a therapeutic area that Roivant may also target, making them competitors.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on developing therapies for neurological and neurodegenerative diseases, competing with Roivant Sciences in the pursuit of innovative treatments in similar domains.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is a global healthcare company that operates in similar therapeutic areas as Roivant, including digital health solutions, making it a competitor in both the pharmaceutical and technological aspects of healthcare.

About

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Show more...
CEO
Matthew Gline
Employees
721
Country
Bermuda
ISIN
BMG762791017
WKN
000A3C4MS

Listings

MU
DE
87S.MU
STU
DE
87S.STU
BOATS
BOATS
ROIV.BOATS
XNAS
US
ROIV

0 Comments

Share your thoughts

FAQ

What is Roivant Sciences stock price today?▼
The current price of ROIV is $34.93 USD — it has increased by +1.51% in the past 24 hours. Watch Roivant Sciences stock price performance more closely on the chart.
What is Roivant Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Roivant Sciences stocks are traded under the ticker ROIV.
Is Roivant Sciences stock price growing?▼
ROIV stock has risen by +0.63% compared to the previous week, the month change is a +0.95% rise, over the last year Roivant Sciences has showed a +170.36% increase.
What is Roivant Sciences market cap?▼
Today Roivant Sciences has the market capitalization of 25.23B
When is the next Roivant Sciences earnings date?▼
Roivant Sciences is going to release the next earnings report on November 16, 2026.
What were Roivant Sciences earnings last quarter?▼
ROIV earnings for the last quarter are -0.33 USD per share, whereas the estimation was -0.3 USD resulting in a -11.71% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Roivant Sciences revenue for the last year?▼
Roivant Sciences revenue for the last year amounts to 8.26M USD.
What is Roivant Sciences net income for the last year?▼
ROIV net income for the last year is -299.77M USD.
How many employees does Roivant Sciences have?▼
As of September 05, 2026, the company has 721 employees.
In which sector is Roivant Sciences located?▼
Roivant Sciences operates in the Health & Wellness sector.
When did Roivant Sciences complete a stock split?▼
Roivant Sciences has not had any recent stock splits.
Where is Roivant Sciences headquartered?▼
Roivant Sciences is headquartered in LONDON, Bermuda.